Company Overview of Oxford Gene Technology IP Limited
Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to advance molecular medicine worldwide. Its products include CytoSure international standards for cytogenomic arrays; CytoSure ISCA UPD arrays that allow the detection of DNA copy number variation with whole chromosome uniparental disomy; CytoSure ISCA UPD arrays that combines long oligo aCGH probes for copy number variation detection; and CytoSure Syndrome Plus v2 arrays for the detection of DNA aberrations across the genome. The company's products also comprise Aneuploidy arrays for the simplified detection of chromosome imbalances; CytoSure single cell aneuploidy arrays to detect aneuploidies when workin...
Begbroke Science Park
Begbroke, OX5 1PF
Founded in 1995
Key Executives for Oxford Gene Technology IP Limited
Founder, Chairman of The Board and Chief Science Advisor
Executive Vice President of R&D
Executive Vice President of Commercial
Compensation as of Fiscal Year 2014.
Oxford Gene Technology IP Limited Key Developments
Oxford Gene Technology Gets £1.2 Million Genomics England Contract
Mar 11 15
Oxford Gene Technology (OGT) announced that it has been awarded a £1.2 million phase two Small Business Research Initiative (SBRI) Healthcarecontract. The contract is to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK. Development of this innovative technology will increase the accuracy and ease of interpreting whole genome genetic variant data by clinicians, supporting more precise treatment decisions. In addition to the analysis of NGS data, the software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH). The results of these tests will be put in context via the use of both public and private databases, providing the clinician with prioritised clinically relevant results. These easy to understand reports will support faster diagnosis and better patient care.
Oxford Gene Technology IP Limited Announces Revenue Results for the Year Ended September 30, 2014
Dec 2 14
Oxford Gene Technology IP Limited announced revenue results for the year ended September 30, 2014. For the period, the company reported total revenue grew by 27% to £15.2 million against £11.9 million a year ago.
Oxford Gene Technology Receives £200,000 Phase One Development SBRI Contract to Develop Innovative NGS Analysis Software
Jul 21 14
Oxford Gene Technology has been awarded a £200,000 phase one development contract by the Small Business Research Initiative (SBRI) healthcare competition. The contract is to develop whole genome Next Generation Sequencing (NGS) analysis software to increase the accuracy, and enhance the analysis of genomic sequence data. This landmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries